
Astrana Health, Inc. (NASDAQ:ASTH - Free Report) - Research analysts at William Blair issued their Q2 2026 EPS estimates for shares of Astrana Health in a research note issued on Wednesday, July 2nd. William Blair analyst R. Daniels anticipates that the company will earn $0.45 per share for the quarter. The consensus estimate for Astrana Health's current full-year earnings is $1.15 per share. William Blair also issued estimates for Astrana Health's Q3 2026 earnings at $0.46 EPS.
Astrana Health (NASDAQ:ASTH - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported $0.14 earnings per share for the quarter, missing the consensus estimate of $0.23 by ($0.09). Astrana Health had a return on equity of 4.90% and a net margin of 1.56%. The business had revenue of $620.39 million for the quarter, compared to analysts' expectations of $628.11 million. During the same period in the previous year, the company earned $0.31 earnings per share. Astrana Health's quarterly revenue was up 53.4% on a year-over-year basis.
Several other equities research analysts also recently weighed in on ASTH. Truist Financial cut their target price on shares of Astrana Health from $50.00 to $46.00 and set a "buy" rating on the stock in a research note on Tuesday, March 18th. Barclays initiated coverage on shares of Astrana Health in a research note on Tuesday, April 1st. They set an "equal weight" rating and a $36.00 target price on the stock. Three equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat, Astrana Health has a consensus rating of "Moderate Buy" and an average target price of $53.29.
View Our Latest Analysis on ASTH
Astrana Health Stock Down 4.5%
ASTH traded down $1.13 during trading hours on Friday, hitting $24.15. 268,276 shares of the company's stock were exchanged, compared to its average volume of 297,766. Astrana Health has a 12-month low of $23.12 and a 12-month high of $63.20. The firm has a 50 day moving average of $26.52 and a 200 day moving average of $30.63. The firm has a market cap of $1.35 billion, a P/E ratio of 35.11, a price-to-earnings-growth ratio of 1.36 and a beta of 0.84. The company has a current ratio of 1.70, a quick ratio of 1.70 and a debt-to-equity ratio of 0.54.
Institutional Investors Weigh In On Astrana Health
A number of large investors have recently modified their holdings of the company. Vanguard Group Inc. increased its position in shares of Astrana Health by 4.5% in the 1st quarter. Vanguard Group Inc. now owns 4,898,992 shares of the company's stock valued at $151,918,000 after purchasing an additional 213,033 shares during the last quarter. Dimensional Fund Advisors LP grew its position in shares of Astrana Health by 10.7% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,045,540 shares of the company's stock valued at $32,968,000 after buying an additional 101,192 shares during the last quarter. 325 Capital LLC grew its position in shares of Astrana Health by 30.3% in the 4th quarter. 325 Capital LLC now owns 886,916 shares of the company's stock valued at $27,964,000 after buying an additional 206,009 shares during the last quarter. SteelPeak Wealth LLC grew its position in shares of Astrana Health by 4.8% in the 1st quarter. SteelPeak Wealth LLC now owns 568,176 shares of the company's stock valued at $17,619,000 after buying an additional 26,192 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its position in shares of Astrana Health by 6.0% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 499,529 shares of the company's stock valued at $15,490,000 after buying an additional 28,200 shares during the last quarter. 52.77% of the stock is owned by hedge funds and other institutional investors.
Astrana Health Company Profile
(
Get Free Report)
Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.
Recommended Stories
Before you consider Astrana Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Astrana Health wasn't on the list.
While Astrana Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.